Immunotherapy in nasopharyngeal carcinoma: current status and unanswered questions
PD‑1 blockade significantly improves progression‑free survival in first‑line treatment of recurrent or metastatic nasopharyngeal carcinoma.
This review highlights that PD‑1 blockade improves survival outcomes for patients with recurrent or metastatic nasopharyngeal carcinoma and identifies critical gaps in sequencing strategies, biomarker development, and resistance mechanisms that must be addressed to optimize therapy.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma